Neuroprotective implant for treatment of glaucoma in phase II trial

Julianne Mobilian

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies.